featured
Risk of Bullous Pemphigoid With Initiation of a DPP-4 Inhibitor vs Second-Generation Sulfonylurea
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-Generation Sulfonylurea
JAMA Dermatol 2020 Jul 22;[EPub Ahead of Print], H Lee, HJ Chung, A Pawar, E Patorno, DH KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.